Every 10-Q that Lightbridge Corp (LTBR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LTBR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LTBR filings page.
Lightbridge Corporation, a nuclear fuel technology developer, reported Q2 2026 results with no revenue and a higher net loss as it accelerates R&D and commercialization efforts. For the quarter ended June 30, 2026, the company posted a net loss of $5.8 million, compared with $3.5 million a year earlier, driven by higher general and administrative expenses of $3.7 million and research and development expenses of $4.0 million.
For the first half of 2026, the net loss was $12.1 million versus $8.3 million in 2025. Cash and cash equivalents rose to $237.5 million from $201.9 million at year-end 2025, primarily from at-the-market equity sales of about 3.8 million shares for net proceeds of $44.4 million and higher interest income of $3.2 million. Management believes existing cash will fund operations for at least 12 months, though substantial additional capital will be required over the longer term.
Operationally, Lightbridge expanded and modified its agreements with Idaho National Laboratory’s operator BEA, with expected aggregate cost reimbursements of $25.2 million and an $18.1 million remaining funding commitment, launched a reconstituted Nuclear Utility Fuel Advisory Board, advanced planning for a potential pilot-scale fuel fabrication facility and Lightbridge Expandable Fuel Facility, and later approved significant new restricted stock and performance-based equity award programs tied to long-term fuel development milestones.
Lightbridge Corporation reported a net loss of $6.3 million for the three months ended March 31, 2026, with no revenue as it continues to focus on developing its next‑generation nuclear fuel. Operating expenses rose to $7.6 million, driven by higher general and administrative and research and development spending.
R&D expenses nearly doubled to $3.3 million, reflecting more engineers, higher bonuses, stock-based awards, and new IT investments, including a high‑performance computer. Lightbridge ended the quarter with strong liquidity, holding $215.7 million in cash and cash equivalents, supported by $18.6 million of net proceeds from at‑the‑market stock sales.
Lightbridge Corporation reported Q3 2025 results highlighting a much stronger balance sheet and continued R&D spend. Cash and cash equivalents were $153,330,134 versus $39,990,827 at year‑end 2024, primarily from at‑the‑market (ATM) equity sales. For the quarter, the company recorded an operating loss of $5,204,200, offset by interest income of $1,104,955, resulting in a net loss of $4,099,245 (vs. $2,656,161 a year ago). Shares outstanding were 30,384,981 as of September 30, 2025; 32,371,338 as of October 31, 2025.
Year‑to‑date, Lightbridge sold 9,854,669 shares under its ATM for net proceeds of $120.4 million, including $57.3 million in Q3 from 3,612,403 shares. Q3 expenses included G&A $3,164,343 and R&D $2,039,857, with R&D focused on Idaho National Laboratory (INL). Cash payments under INL umbrella agreements are estimated at ~$6.8 million, with $2.0 million obligations outstanding. Subsequent to quarter‑end, ATM sales added 1,891,613 shares for ~$42.0 million net. The company extended its INL agreements (SPPA to 12 years; CRADA to 2032) and entered a $0.8 million safety analysis software agreement. Authorized common shares increased to 100,000,000 in May 2025.
Lightbridge Corporation (LTBR) reported a stronger liquidity position at June 30, 2025, with $97.9 million in cash and cash equivalents versus $40.0 million at December 31, 2024, largely driven by at‑the‑market (ATM) equity sales that generated $63.1 million of net proceeds in the six months ended June 30, 2025. The company recorded a net loss of $8.29 million for the six months ended June 30, 2025 (basic and diluted loss per share $0.40), compared with a $5.19 million loss in the prior year period. Operating expenses rose as R&D spending increased to $3.3 million and G&A to $6.0 million for the six months.
Lightbridge continues R&D collaborations with Idaho National Laboratory under SPPA/CRADA agreements, including recent modifications that raised total estimated reimbursable costs to $6.8 million with a $2.8 million remaining balance at June 30, 2025. The company expanded authorized common shares to 100 million, established a new Form S‑3 shelf (up to $150 million) and an Open Market Sale Agreement with Jefferies for up to $75 million in ATM capacity, supporting near‑term financing flexibility while pursuing fuel qualification milestones and pilot fabrication planning.